From John Money to Modern Gender Clinics: An Insider Speaks - Dr. Quentin Van Meter (#28)
11 August 2025
With Dr. Quentin Van Meter
North America
Dr. Quentin Van Meter, a paediatric endocrinologist who trained at Johns Hopkins and treated his first gender-distressed child in 1993, offers an insider account of how youth gender medicine developed without an adequate evidence base. His testimony maps closely onto the findings of systematic reviews across Europe — from the Cass Review in England to health authority restrictions in Sweden, Finland and Denmark — that have each documented the same evidentiary gap.
Dr. Quentin Van Meter holds an unusual position in the debate over medical interventions for gender-distressed young people. A paediatric endocrinologist with more than four decades of clinical experience, he was present at the field's earliest organised expression during his fellowship at Johns Hopkins, where he worked alongside John Money, the psychologist whose framework around gender malleability became the intellectual foundation of later clinical practice. Van Meter's account therefore draws not from secondary literature but from direct professional proximity to the field's founding assumptions. The episode traces how Money's theories became progressively embedded in clinical protocols and eventually in international standards of care issued by organisations such as WPATH. Van Meter characterises WPATH's trajectory as a departure from scientific rigour, arguing that its guidance has reflected ideological consensus more than systematic evidence. This contention has since been placed on record by formal independent reviews: the Cass Review in England and systematic reviews by health authorities in Sweden and Finland each identified low or very low certainty evidence underlying established protocols for gender-distressed minors. Among the specific clinical concerns Van Meter raises is a dementia risk he associates with prolonged GnRH analogue use, citing emerging research on the cognitive effects of sustained sex hormone suppression in adolescence. He also puts the progression rate from puberty blockers to cross-sex hormones at approximately 98% — a figure with direct bearing on the informed-consent argument that blockers constitute a reversible diagnostic pause. Nordic health authorities cited comparable progression data when restricting paediatric gender pathways in Sweden, Finland and Denmark. If suppression functions in practice as a gateway rather than a pause, the clinical and ethical framing of the treatment changes substantially. Van Meter also describes his departure from the American Academy of Pediatrics after thirty-seven years, which he attributes to a policy on transgender care he regards as adopted without adequate evidence review. The AAP's 2018 affirmative-care policy attracted methodological criticism, and the organisation subsequently commissioned an independent evidence review under external pressure. The gap between professional-body positions and the underlying evidence base is a pattern that European systematic reviews have since documented in detail, and it underpins legal challenges and legislative scrutiny in multiple European jurisdictions, including the Bell v Tavistock litigation in England. The episode's central argument — that no biological basis exists for the concept of an incongruent gender identity — locates the discussion at a foundational scientific level rather than a purely policy one. The evidentiary questions it raises are precisely those that prompted England's NHS to commission the Cass Review, Sweden's National Board of Health and Welfare to restrict paediatric gender medicine to research settings, and clinical and legal bodies across Europe to re-examine the basis on which these interventions were authorised. Van Meter's account, spanning more than three decades of clinical observation, provides a rare longitudinal perspective on how the field arrived at its present state.
